EGFR and bone metastasis: The baseline characteristics of patients in the three groups (uncommon EGFR mutations vs 19del vs L858R) were generally similar, except that baseline bone metastasis developed less frequently in patients with uncommon EGFR mutations (31.1%), when compared with those harboring 19del (43.8%) or L858R mutation (48.0%) (p = 0.02).